Date: July 26, 2022
Contact: Rick Rosen, MD, MPH, frosen@co.slo.ca.us, 805-781-5500

**Upcoming CDC COCA Call on Novavax**
Best practices for the newest COVID-19 vaccine

**Background**
- The COVID-19 Novavax vaccine is a two-dose primary series (3–8 weeks apart) for adults ages 18 and older.
- It is a protein subunit vaccine (common technology used to develop previous vaccines). Unlike Pfizer and Moderna vaccines, it does not use mRNA technology.
- Novavax may receive uptake by individuals not yet vaccinated against COVID-19. Note that some may have a personal preference for Novavax over the mRNA vaccines.
- Novavax has not been authorized as a booster dose and should not be administered as a booster dose at this time.

**COCA Call Details**
During this COCA Call, presenters will discuss CDC’s new guidance on the Novavax COVID-19 vaccine for adults ages 18 years and older, including adults who are moderately or severely immunocompromised.

- **What:** CDC Clinician Outreach and Communication Activity (COCA) Call: Recommendations for the Novavax COVID-19 Vaccine Primary Series in Adults 18 and Older
- **When:** Thursday, July 28, from 11:00 AM – 12:00 PM PST
- **Presenters:**
  - Evelyn Twentyman, MD, MPH, Lead, Vaccine Policy Unit, COVID-19 Response, Centers for Disease Control and Prevention
  - Elisha Hall, PhD, RD, Lead, Clinical Guidelines Vaccine Policy Unit, COVID-19 Response, Centers for Disease Control and Prevention
  - Tanya Myers, PhD, MSc, Co-Lead, v-safe Team, Immunization Safety Office, National Center for Emerging and Zoonotic Infectious Diseases, Centers for Disease Control and Prevention
- **To join the call on June 28** (no pre-registration necessary):
  www.zoomgov.com/j/1612728470

For more information: www.emergency.cdc.gov/coca/calls/2022/callinfo_072822.asp